DHR Earnings Prediction
The chart below shows how DHR performed 10 days before and after its earnings report, based on data from the past quarters. Typically, DHR sees a +0.54% change in stock price 10 days leading up to the earnings, and a -0.55% change 10 days following the report. On the earnings day itself, the stock moves by -0.85%. This data can give you a slight idea of what to expect for the next quarter's release.
DHR Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
5.80B
-15.64%
0.96%
Gross Margin
58.66%
0.79%
-1.73%
Operating Margin
20.35%
-3.14%
0.05%
Net Margin
14.11%
-14.12%
-10.64%
EPS
1.12
-25.83%
-8.20%
No Data Available
DHR Earnings Analysis
Danaher Corporation Corporation (DHR.N) Earnings Conference Call
Positive
Core Revenue Growth: Sales were $5.8 billion in the third quarter and we delivered 0.5% core revenue growth.
Developed Markets Revenue Growth: Geographically, core revenues in developed markets increased low single-digits with low single-digit growth in North America and mid-single-digit growth in Western Europe.
Profit Margin Analysis: Our gross profit margin for the second quarter was 58.7% and our adjusted operating profit margin of 27.5% was down 10 basis points as accelerated investments in innovation offset the favorable impact of cost-saving initiatives.
Free Cash Flow Performance: Adjusted diluted net earnings per common share of $1.71 were essentially flat year-over-year and we generated $1.2 billion of free cash flow in the quarter and $3.8 billion year-to-date, resulting in a year-to-date free cash flow to net income conversion ratio of 135%.
Life Sciences Revenue Decline: Core revenue in our Life Sciences segment decreased by 2%, in line with our expectations.
Negative
Core Revenue Growth: Sales were $5.8 billion in the third quarter and we delivered 0.5% core revenue growth.
Developed Markets Revenue Growth: Geographically, core revenues in developed markets increased low single-digits with low single-digit growth in North America and mid-single-digit growth in Western Europe.
Profit Margin Analysis: Our gross profit margin for the second quarter was 58.7% and our adjusted operating profit margin of 27.5% was down 10 basis points as accelerated investments in innovation offset the favorable impact of cost saving initiatives.
Free Cash Flow Performance: Adjusted diluted net earnings per common share of $1.71 were essentially flat year-over-year and we generated $1.2 billion of free cash flow in the quarter and $3.8 billion year-to-date, resulting in a year-to-date free cash flow to net income conversion ratio of 135%.
Biotechnology Segment Performance: Core revenue in our Biotechnology segment was flat year-over-year, with our bioprocessing business up low single-digits and our discovery and medical business down high single-digits.
DHR FAQs
How does DHR typically perform around its earnings report dates?
Is Danaher Corporation (DHR) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
DHR Earning Call Sentiment
Danaher Corporation (DHR) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
DHR.N
1.95%Positive
The earnings call reveals several challenges: regulatory issues, supply chain problems, and economic factors affecting growth, especially in China. Despite stable market conditions in life sciences, there's a decline in capital equipment sales. Financial performance shows marginal sales growth but declining profit margins. The Q&A section highlights uncertainties, particularly in China. The combination of these factors, along with a flat adjusted EPS and cautious guidance, suggests a negative outlook for the stock price over the next two weeks.